Commure
AI platform for clinical documentation and revenue cycle work
Our take
Commure is a healthcare AI company backed and incubated by General Catalyst. After merging with Athelas in 2023 at a reported $6B combined valuation, it assembled a product suite that covers ambient AI documentation (bolstered by the Augmedix acquisition), revenue cycle automation, practice management and billing, clinician workflow software from PatientKeeper, staff safety hardware, and care management from Memora Health. Its buyers are large health systems and multi-site medical groups, typically ones looking to consolidate AI scribing and RCM automation with a single vendor.
Commure reports deployments across more than 130 health systems and 3,000+ sites of care, with named customers including HCA Healthcare, Tenet, Jefferson, and Providence, and integrations into 60+ EHRs. It raised $200M from General Catalyst's Customer Value Fund in June 2025 and another $70M in May 2026 at a $7B post-money valuation, with Sequoia participating. The bet for buyers is scale and breadth; the tradeoff is a portfolio stitched together through many acquisitions, where maturity differs product by product.
What it does
- Ambient AI clinical documentation (scribing)
- Revenue cycle automation across front, middle, and back office
- Practice management and billing for medical groups
- Clinician workflow tools (PatientKeeper lineage)
- Staff duress and safety badges (Strongline)
- Patient engagement and care management (Memora)
Where it's strong
- Deep General Catalyst backing and health system relationships give it staying power and large reference customers like HCA.
- Breadth is unusual: one contract can cover ambient documentation, RCM automation, and practice management.
- Claims deployment across 130+ health systems and 3,000+ sites, so it has real enterprise scale.
What buyers should weigh
- The platform is an assembly of acquired products (Athelas, PatientKeeper, Augmedix, Memora), so integration depth varies by module.
- Fast growth by M&A means product roadmaps and account teams can shift; ask which products are strategic.
- Its marquee metrics (85%+ touchless RCM work) are vendor-reported and worth validating in a pilot.
Latest
Raised $200M in growth financing from General Catalyst's Customer Value Fund in June 2025, then a further $70M in May 2026 at a $7B valuation.
Also in RCM Automation Platforms
Notable
AI agents across intake, auth, and revenue workflows
Trase
Governed AI agents for healthcare back-office work
GenHealth.ai
An agentic OS for healthcare administration
CombineHealth
Named AI agents that work the revenue cycle end to end
Track this market
First Pass covers RCM Automation Platforms and the rest of the getting-paid stack every week.